The goal of the proposed study is to elucidate the mechanisms of cell transformation by oncogene ros. The v-ros oncogene carried by avian sarcoma virus UR2 codes for a receptor-like protein tyrosine kinase (PTK) bearing close homology in its PTK domain with those of insulin and insulin-like growth factor I receptors. The focus of this study will be on the identification of the properties and cellular substrates important for the cell transforming and signalling processes of v- and c-ros proteins. In addition, effect of protein tyrosine phosphatases (PTPases) on the ros-mediated cell transformation will also be investigated. These problems will be approached by using specific ros mutants in chicken and mammalian cell transformation as well as monoclonal antibodies specific to individual substrates of the ros protein.
The Specific Aims are: 1. Identification of ros sequences modulating its kinase activity, substrate interaction and transforming ability. 2. Isolation of monoclonal antibodies specific for the substrates of ros. 3. Identification of biochemical properties, especially the substrate(s) important for cell transformation by ros. 4. Characterization of the expression and signal transducing function of protooncogene c-ros. 5. Study of the effect of PTPases on cell transforming and signalling function of ros. It is hoped that this study will further our understanding of the mechanism of cell transformation by this receptor-like PTK oncogene.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA029339-13
Application #
3168658
Study Section
Virology Study Section (VR)
Project Start
1981-02-01
Project End
1997-02-28
Budget Start
1992-03-05
Budget End
1993-02-28
Support Year
13
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Schlosshauer, Peter W; Li, Wei; Lin, Kai-Ti et al. (2009) Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. Gynecol Oncol 114:516-22
Zhang, Weizhou; Cheng, George Zhi; Gong, Jianli et al. (2008) RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem 283:16416-26
Cheng, George Z; Zhang, Wei Zhou; Sun, Mei et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283:14665-73
Cheng, George Z; Park, Sungman; Shu, Shaokun et al. (2008) Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8:2-6
Cheng, George Z; Zhang, Weizhou; Wang, Lu-Hai (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68:957-60
Uttamsingh, S; Bao, X; Nguyen, K T et al. (2008) Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27:2626-34
Cheng, George Z; Chan, Joseph; Wang, Qi et al. (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979-87
Wang, Lu-Hai; Chan, Joseph L-K; Li, Wei (2007) Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int J Cancer 121:157-64
Zhang, Weizhou; Zong, Cong S; Hermanto, Ulrich et al. (2006) RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol Cell Biol 26:413-24
Wang, Lu-Hai (2004) Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 71:361-7

Showing the most recent 10 out of 45 publications